Friday's top analyst upgrades, downgrades and initiations include Apple, Citrix Systems, Kythera Biopharmaceuticals, Mylan, Netflix and Weatherford International.
In a new report from RBC, while they think the selling and profit taking in biotechs could go on, they also hold fast that industry fundamentals are still very positive.
Deutsche Bank says that investors have misread the current instances floating around two leading biotech stocks, and they both should be bought now on any continuing weakness.
Thursday's top analyst upgrades, downgrades and initiations seen from Wall Street research calls include Crocs, Halliburton, Nuance Communications, Staples and Yelp.
ThinkstockLooking back at 2014, biotechs had a phenomenal year, and this looks to continue into 2015. The NYSE Arca Biotech index was up over 45% for 2014, and Wells Fargo expects that…
One sector that could be poised to do well could be the biotech arena, and the team at RBC has five top stocks for investors to focus on as best ideas.
At least five upcoming dates could be big days in December, for better or worse, for individual biotech stocks.
ThinkstockStocks have enjoyed yet another wonderful year in 2014, and the bull market is now more than five and a half years old. With the S&P 500 index up almost 14% year-to-date…
ThinkstockIf any sector has had an up and down 2014, it would be the biotech. A massive sell-off in the spring and in the fall has given some biotech investors a serious…
With the U.S. markets hitting all-time highs again, insider sellers are more than happy to step up and unload some stock.
These are the top analyst upgrades and downgrades featured by 24/7 Wall St. on Monday, October 13, 2014.
These are the top analyst upgrades, downgrades and initiations seen on Tuesday, October 7, 2014.
For many of the top biotech companies, orphan drugs have morphed into huge winners and have even generated other streams of revenue.
These are the top analyst upgrades and downgrades covered by 24/7 Wall St. on Friday, September 5, 2014.
ThinkstockA brand new research report from RBC highlights more than 50 biotech event catalysts that are on the horizon. These are trial data, FDA decisions and company presentations coming soon. The analysts screened…
